-
公开(公告)号：US10413592B2
公开(公告)日：2019-09-17
申请号：US15053116
申请日：2016-02-25
申请人： FERRING B.V.
发明人： Joan-Carles Arce , Jane Ruman
摘要： The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian response to controlled ovarian stimulation.
-
公开(公告)号：US11291708B2
公开(公告)日：2022-04-05
申请号：US16851260
申请日：2020-04-17
申请人： FERRING B.V.
发明人： Joan-Carles Arce
IPC分类号： A61K38/24
摘要： Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.
-
公开(公告)号：US10183029B2
公开(公告)日：2019-01-22
申请号：US15408256
申请日：2017-01-17
申请人： Ferring B.V.
发明人： Joan-Carles Arce
IPC分类号： A61B17/435 , A61K31/57 , A61K31/404 , A61K38/11 , A61K38/12 , A61K9/00 , A61K45/06 , A61K31/4045 , A61K31/565
摘要： The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.
-
公开(公告)号：US20200345814A1
公开(公告)日：2020-11-05
申请号：US16851260
申请日：2020-04-17
申请人： FERRING B.V.
发明人： Joan-Carles Arce
IPC分类号： A61K38/24
摘要： Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.
-
公开(公告)号：US20160250296A1
公开(公告)日：2016-09-01
申请号：US15053116
申请日：2016-02-25
申请人： FERRING B.V.
发明人： Joan-Carles Arce , Jane Ruman
CPC分类号： A61K38/24 , A61B17/425 , A61K45/06 , C12N5/0604 , C12N5/0609 , G01N33/74
摘要： The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian response to controlled ovarian stimulation.
摘要翻译： 本发明涉及使用高度纯化的促黄体素（HP-hMG）在受控的卵巢刺激中刺激卵泡发育的改善的辅助生殖技术，特别是在受控卵巢刺激的卵巢反应高的妇女中。
-
6.发明申请公开(公告)号：US20160175283A1
公开(公告)日：2016-06-23
申请号：US14643307
申请日：2015-03-10
申请人： Ferring B.V.
发明人： Joan-Carles Arce
IPC分类号： A61K31/404 , A61B17/435
CPC分类号： A61K31/57 , A61B17/435 , A61K9/0019 , A61K9/0034 , A61K31/404 , A61K31/4045 , A61K31/565 , A61K38/11 , A61K38/12 , A61K45/06 , A61K2300/00
摘要： The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.
摘要翻译： 本发明涉及催产素受体拮抗剂在经历胚胎移植的雌性中作为辅助生殖技术的一部分的用途。 特别地，提供了用于在接受胚胎移植的女性受试者中增加持续的植入率，增加持续怀孕率，增加临床怀孕率和/或增加活产率的方法。 具体地，当子宫内膜接受胚胎植入和/或当胚胎达到囊胚期时，拮抗剂在黄体期释放。
-
公开(公告)号：US20220370567A1
公开(公告)日：2022-11-24
申请号：US17709305
申请日：2022-03-30
申请人： FERRING B.V.
发明人： Joan-Carles Arce
IPC分类号： A61K38/24
摘要： Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.
-
公开(公告)号：US10688106B2
公开(公告)日：2020-06-23
申请号：US15538639
申请日：2015-12-21
申请人： Ferring B.V.
发明人： Joan-Carles Arce
IPC分类号： A61K31/57 , A61K31/404 , A61B17/435 , A61K38/095 , A61K38/12 , A61K45/06 , A61K31/4045 , A61K31/565 , A61K9/00
摘要： The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.
-
公开(公告)号：US20180028620A1
公开(公告)日：2018-02-01
申请号：US15637962
申请日：2017-06-29
申请人： Ferring B.V.
发明人： Joan-Carles Arce
IPC分类号： A61K38/24
摘要： Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.
-
公开(公告)号：US11351228B2
公开(公告)日：2022-06-07
申请号：US16555688
申请日：2019-08-29
申请人： FERRING B.V.
发明人： Joan-Carles Arce , Jane Ruman
摘要： The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian response to controlled ovarian stimulation.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.012 秒)